Milestone Pharmaceuticals announced U.S. availability of CARDAMYST (etripamil) nasal spray, FDA-approved for converting acute PSVT episodes in adults, with launch in mid-February 2026 supported by a national sales force and patient assistance program capping copays at $25 for eligible patients.1
CARDAMYST is the first self-administered nasal spray for PSVT in over 30 years, approved December 12, 2025, enabling patient self-management without medical oversight.1
Prior presentations at ACC 2025 (March 29-31) featured NODE-303 trial data by Dr. James Ip, showing etripamil's consistent conversion of multiple PSVT episodes to sinus rhythm.2
Etripamil is in Phase 2 for pediatric PSVT and Phase 3 for AFib-RVR; company has history of ACC presentations on self-administered etripamil data from large safety trials.34
Sources:
1. https://www.globenewswire.com/news-release/2026/01/26/3225590/0/en/Milestone-Pharmaceuticals-Announces-U-S-Availability-of-CARDAMYST-etripamil-Nasal-Spray-the-First-and-Only-FDA-Approved-Self-Administered-Treatment-for-Adults-with-Paroxysmal-Supra.html
2. https://www.clinicaltrialvanguard.com/news/milestone-pharmaceuticals-to-present-etripamil-data-at-acc/
3. https://milestonepharma.com/news-item/milestone-pharmaceuticals-announces-etripamil-data-demonstrating-patients-ability-to-self-manage-recurring-psvt-presented-at-the-american-college-of-cardiology-annual-meeting-2/
4. https://milestonepharma.com/news-item/milestone-pharmaceuticals-to-present-data-on-etripamil-at-the-american-college-of-cardiology-and-european-heart-rhythm-association-annual-conferences/